Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data. (Q31054926)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Hoa Q Nguyen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ernesto Callegari

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

R Scott Obach

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

8 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

Drug Metabolism and Disposition

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

781-791

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26956641%20AND%20SRC:MED&resulttype=core&format=json

Solubility and acid—base behaviour of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Predicting circulating human metabolites: how good are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Drug metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prolonged sedation due to accumulation of conjugated metabolites of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Comparison of midazolam and simvastatin as cytochrome P450 3A probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Relationship between plasma concentration and effect of midazolam after oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Role of pharmacologically active metabolites in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacokinetics and bioavailability of midazolam in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

21 January 2018

Drug metabolite kinetics

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Interaction between grapefruit juice and midazolam in humans*

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Midazolam: A review of therapeutic uses and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Predicting Clearance in Humans from In Vitro Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

First-pass metabolism of midazolam by the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

The pharmacokinetics of midazolam in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Validated assays for human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Prediction of intestinal first-pass drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601

Practical identifiability analysis of large environmental simulation models

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.068601